Work

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study

Year: 2015

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-015-2882-9

Authors: Anthony W. Tolcher, Patricia LoRusso, Jennifer Arzt, Todd A. Busman, Guinan Lian, Niki S. Rudersdorf, Carol Ann Vanderwal, Jeffrey F. Waring, Jianning Yang, Kyle D. Holen, Lee S. Rosen

Institutions: South Texas Accelerated Research Therapeutics, Yale Cancer Center, Yale University, AbbVie (United States), University of California, Los Angeles

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: AbbVie, Genentech

OpenAlex ID: W2277993502

FWCI: 1.419

Cites: 23

Cited by: 40

Related to: 10